FI903688A0 - Nya aminer, deras anvaendning och framstaellning. - Google Patents

Nya aminer, deras anvaendning och framstaellning.

Info

Publication number
FI903688A0
FI903688A0 FI903688A FI903688A FI903688A0 FI 903688 A0 FI903688 A0 FI 903688A0 FI 903688 A FI903688 A FI 903688A FI 903688 A FI903688 A FI 903688A FI 903688 A0 FI903688 A0 FI 903688A0
Authority
FI
Finland
Prior art keywords
aminer
nya
methyl
preparing
same
Prior art date
Application number
FI903688A
Other languages
English (en)
Other versions
FI109900B (fi
Inventor
Nils Aoke Joensson
Bengt Aoke Sparf
Lembit Mikiver
Pinchas Moses
Lisbet Nilvebrant
Gunilla Glas
Original Assignee
Kabivitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20371146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI903688(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kabivitrum Ab filed Critical Kabivitrum Ab
Publication of FI903688A0 publication Critical patent/FI903688A0/fi
Application granted granted Critical
Publication of FI109900B publication Critical patent/FI109900B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
FI903688A 1988-01-22 1990-07-20 Menetelmä farmaseuttisesti aktiivisten 3,3-difenyylipropyyliamiinien valmistamiseksi FI109900B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8800207A SE8800207D0 (sv) 1988-01-22 1988-01-22 Nya aminer, deras anvendning och framstellning
PCT/SE1989/000016 WO1989006644A1 (en) 1988-01-22 1989-01-20 New amines, their use and preparation

Publications (2)

Publication Number Publication Date
FI903688A0 true FI903688A0 (fi) 1990-07-20
FI109900B FI109900B (fi) 2002-10-31

Family

ID=20371146

Family Applications (1)

Application Number Title Priority Date Filing Date
FI903688A FI109900B (fi) 1988-01-22 1990-07-20 Menetelmä farmaseuttisesti aktiivisten 3,3-difenyylipropyyliamiinien valmistamiseksi

Country Status (17)

Country Link
EP (2) EP0354234A1 (fi)
JP (1) JP2664503B2 (fi)
AT (1) ATE65990T1 (fi)
AU (1) AU635493B2 (fi)
CA (1) CA1340223C (fi)
DE (2) DE68900180D1 (fi)
DK (1) DK172103B1 (fi)
ES (1) ES2029384T4 (fi)
FI (1) FI109900B (fi)
GR (1) GR3002854T3 (fi)
HK (1) HK64494A (fi)
HU (2) HU212729B (fi)
LU (1) LU90259I2 (fi)
NL (1) NL980020I2 (fi)
NO (2) NO173496C (fi)
SE (1) SE8800207D0 (fi)
WO (1) WO1989006644A1 (fi)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
ZA969363B (en) * 1995-11-08 1997-11-18 Smithkline Beecham Corp An improved process for preparing aromatic ring-fused cyclopentane derivatives.
JP2000515525A (ja) * 1996-07-19 2000-11-21 アベーグ，グンナー 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン
KR20000057548A (ko) * 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
SE9701144D0 (sv) * 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
EP0957073A1 (en) 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
MY127946A (en) 1998-08-27 2007-01-31 Pharmacia & Upjohn Ab Therapeutic formulation for administering tolterodine with controlled release
DE29923134U1 (de) * 1999-11-16 2000-06-29 Schwarz Pharma Ag, 40789 Monheim Stabile Salze neuartiger Derviate von 3,3-Diphenylpropylaminen
SE9904850D0 (sv) 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
US6566537B2 (en) 1999-12-30 2003-05-20 Pharmacia Ab Process and intermediates
DE10028443C1 (de) * 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen
DE10033016A1 (de) * 2000-07-07 2002-01-24 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen
AU2002342313A1 (en) * 2001-11-05 2003-05-19 Pharmacia And Upjohn Company Antimuscarinic aerosol
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
CA2492121A1 (en) 2002-07-08 2004-01-15 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
WO2004014853A1 (en) 2002-07-31 2004-02-19 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
AU2002321711A1 (en) 2002-08-09 2004-02-25 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives useful as muscarinic receptor antagonist
US7288562B2 (en) 2002-08-23 2007-10-30 Ranbaxy Laboratories Limited Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
JP2006518707A (ja) 2002-12-10 2006-08-17 ランバクシー ラボラトリーズ リミテッド ムスカリン様受容体アンタゴニストとしての３，６−二置換アザビシクロ［３．１．０］ヘキサン誘導体
WO2004054560A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
AU2002347552A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
AU2002347553A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
KR20050096147A (ko) 2003-01-22 2005-10-05 피저 헬스 에이비 비뇨기 장애 치료용 톨테로딘 및 다른 항무스카린제의감소량 투여
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1603862A1 (en) * 2003-03-06 2005-12-14 Ranbaxy Laboratories Limited 3,3-diarylpropylamine derivatives and processes for isolation thereof
AU2003304037A1 (en) * 2003-04-08 2004-11-01 Hetero Drugs Limited Novel polymorphs of tolterodine tartrate
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
US7517905B2 (en) 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
JP2006514978A (ja) 2003-04-10 2006-05-18 ランバクシー ラボラトリーズ リミテッド ムスカリン受容体アンタゴニストである置換アザビシクロヘキサン誘導体
US7560479B2 (en) 2003-04-10 2009-07-14 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0409302A (pt) 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
JP2006524677A (ja) 2003-04-25 2006-11-02 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗ムスカリン活性を有するハロゲン置換３，３−ジフェニルプロピルアミン（トルテロジン）
JP2007502865A (ja) * 2003-05-23 2007-02-15 ブリッジ ファーマ、インコーポレイテッド 平滑筋鎮痙剤
ES2235648B1 (es) * 2003-12-22 2006-11-01 Ragactives, S.L. Procedimiento para la obtencion de tolterodina.
CA2551501C (en) * 2003-12-24 2012-05-29 Cipla Limited Tolterodine, compositions and uses thereof, and preparation of the same
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
JP4513535B2 (ja) * 2004-12-03 2010-07-28 住友化学株式会社 トルテロジンの製造方法
EP1838659B1 (en) * 2004-12-24 2015-07-15 LEK Pharmaceuticals d.d. Process for preparation of n,n-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine
ITMI20050249A1 (it) 2005-02-18 2006-08-19 Dipharma Spa Procedimento per la preparazione di tolterodina
WO2007039918A1 (en) * 2005-10-06 2007-04-12 Natco Pharma Limited Novel process for the preparation of tolterodine
CA2626612A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
TW200733975A (en) * 2005-12-20 2007-09-16 Pfizer Prod Inc Pharmaceutical combination for the treatment of luts
ITMI20060110A1 (it) * 2006-01-24 2007-07-25 Dipharma Spa Procedimento per la purificazione di tolterodina
EA016203B1 (ru) 2006-03-20 2012-03-30 Пфайзер Лимитед Производные амина
BRPI0712842A2 (pt) 2006-06-12 2012-07-24 Sanol Arznei Schwarz Gmbh internediÁrio quiral, processo para produÇço do mesmo e seu emprego na fabricaÇço da tolterodina, fesoterodina ou o metabàlito ativo das mesmas.
WO2007147547A1 (en) 2006-06-20 2007-12-27 Lek Pharmaceuticals D.D. Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-n-alkyl-3-phenylpropylamines
CZ302585B6 (cs) * 2007-02-26 2011-07-20 Zentiva, A. S. Krystalická sul 2-[(1R)-3-[bis(1-methylethyl)amino]-1-fenylpropyl]-4-methylfenolu s kyselinou (2R,3R)-2,3-dihydroxybutandiovou
EA016325B1 (ru) * 2006-08-09 2012-04-30 Зентива, К.С. Способ получения кристаллического (r)-толтеродина тартрата
ITMI20082055A1 (it) * 2008-11-19 2009-02-18 Dipharma Francis Srl Procedimento per la preparazione di (r)-tolterodina base libera
PL2416761T3 (pl) * 2009-05-11 2015-07-31 Ratiopharm Gmbh Desfezoterodyna w postaci soli kwasu winowego
IL210279A0 (en) 2009-12-25 2011-03-31 Dexcel Pharma Technologies Ltd Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients
EP2364966A1 (en) 2010-03-09 2011-09-14 LEK Pharmaceuticals d.d. Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-3-phenylpropylamines, intermediates for making hydroxytolterodine
CN102329244A (zh) * 2010-07-13 2012-01-25 凯瑞斯德生化(苏州)有限公司 一种rs-托特罗定的制备方法及中间体化合物
ITMI20110410A1 (it) * 2011-03-15 2012-09-16 Cambrex Profarmaco Milano Srl Procedimento per la preparazione di (r)-tolterodina l-tartrato di forma cristallina definita
ITMI20121232A1 (it) 2012-07-16 2014-01-17 Cambrex Profarmaco Milano Srl Procedimento per la preparazione di 2-(3-n,n-diisopropilamino-1-fenilpropil)-4-idrossimetil-fenolo e suoi derivati
CN110372571B (zh) 2018-04-12 2022-11-15 中国科学院大连化学物理研究所 一种2-(2,2-二芳基乙基)-环胺衍生物或盐及合成和应用与组合物
WO2022256480A1 (en) * 2021-06-03 2022-12-08 Conagen Inc. Arylcoumarin synthesis with azeotropic removal of water

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK111894A (fi) * 1962-11-15
GB1169945A (en) * 1966-08-25 1969-11-05 Geistlich Soehne Ag Pharmaceutical Compositions containing Diphenylalkyl-amine Derivatives
GB1169944A (en) * 1966-08-25 1969-11-05 Geistlich Soehne Ag Novel 3,3-Diphenylpropylamines and processes for the preparation thereof

Also Published As

Publication number Publication date
SE8800207D0 (sv) 1988-01-22
DK172590A (da) 1990-07-19
GR3002854T3 (en) 1993-01-25
JP2664503B2 (ja) 1997-10-15
ES2029384T4 (es) 2011-05-30
DK172103B1 (da) 1997-10-27
FI109900B (fi) 2002-10-31
NO1998023I1 (no) 1998-10-20
CA1340223C (en) 1998-12-15
DK172590D0 (da) 1990-07-19
EP0354234A1 (en) 1990-02-14
ES2029384T3 (es) 1992-08-01
HU210603A9 (en) 1995-05-29
DE68900180D1 (de) 1991-09-12
HU212729B (en) 1996-10-28
NL980020I1 (nl) 1998-09-01
HUT58040A (en) 1992-01-28
NO173496B (no) 1993-09-13
JPH03503163A (ja) 1991-07-18
NO903085L (no) 1990-07-11
HU891069D0 (en) 1991-11-28
NL980020I2 (nl) 1999-02-01
NO173496C (no) 1993-12-22
DE19875024I2 (de) 2002-09-26
EP0325571B1 (en) 1991-08-07
AU2932989A (en) 1989-08-11
HK64494A (en) 1994-07-15
AU635493B2 (en) 1993-03-25
LU90259I2 (fr) 1998-09-16
NO903085D0 (no) 1990-07-11
WO1989006644A1 (en) 1989-07-27
ATE65990T1 (de) 1991-08-15
EP0325571A1 (en) 1989-07-26

Similar Documents

Publication Publication Date Title
FI903688A0 (fi) Nya aminer, deras anvaendning och framstaellning.
FI952179A (fi) Uusia 3,3-difenyylipropyyliamiineja, niiden käyttö ja valmistus
ZA932168B (en) Naphthylalkylamines, process for preparing them and pharmaceutical compositions containing them
FR2695387B1 (fr) Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
GR3017599T3 (en) Thiochromane derivatives, process for their preparation and pharmaceutical compositions containing them.
DE68905363D1 (de) Heterotetracyclische laktamderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitungen, die sie enthalten.
GR3021765T3 (en) Aminoalkylchomones, process for their preparation and pharmaceutical compositions containing them.
ATE39352T1 (de) Ergolinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: PHARMACIA & UPJOHN AB

GB Transfer or assigment of application

Owner name: PHARMACIA & UPJOHN AB

HC Name/ company changed in application

Owner name: PHARMACIA & UPJOHN AB

FG Patent granted

Owner name: PHARMACIA & UPJOHN AB

SPCG Supplementary protection certificate granted

Spc suppl protection certif: L197

Extension date: 20120904

MA Patent expired